Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study
Abstract Aim The objective of this study was to evaluate the reported associations between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and a variety of proton pump inhibitors (PPI) through analysis of the reports extracted from the Food and Drug Administration Adverse Event...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-05-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-022-02818-3 |
| _version_ | 1818240809427795968 |
|---|---|
| author | Mengmeng Wang Lingjian Zhang Min Jia Junyan Wang Zhiwen Shen Shuyue Wang Xinghui Zhang Jing Xu Zheng Zheng Xuanrui Lv Xiaoyu Zong Hui Li Jin Zhou Tong Meng Mingzhu Chen Bin Zhao Jian Gong |
| author_facet | Mengmeng Wang Lingjian Zhang Min Jia Junyan Wang Zhiwen Shen Shuyue Wang Xinghui Zhang Jing Xu Zheng Zheng Xuanrui Lv Xiaoyu Zong Hui Li Jin Zhou Tong Meng Mingzhu Chen Bin Zhao Jian Gong |
| author_sort | Mengmeng Wang |
| collection | DOAJ |
| description | Abstract Aim The objective of this study was to evaluate the reported associations between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and a variety of proton pump inhibitors (PPI) through analysis of the reports extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods FAERS reports from January 2004 to March 2020 were used to conduct disproportionality and Bayesian analyses. The definition of SIADH relied on the preferred terms provided by the Medical Dictionary for Regulatory Activities. The time to onset, mortality, and hospitalization rates of PPI-related SIADH were also investigated. Results The study identified a total of 273 reports of PPI-associated SIADH, which appeared to influence more elderly than middle-aged patients (71.1% vs. 12.5%). Women were more affected than men (48.7% vs. 41.8%). Rabeprazole had a stronger SIADH association than other PPIs based on the highest reporting odds ratio (reporting odds ratio = 13.3, 95% confidence interval (CI) = 7.2, 24.9), proportional reporting ratio (proportional reporting ratio = 13.3, χ2 = 113.7), and empirical Bayes geometric mean (empirical Bayes geometric mean = 13.3, 95% CI = 7.9). The median time to SIADH onset was 22 (interquartile range 6–692) days after PPI administration. PPI-associated SIADH generally led to a 2.95% fatality rate and a 79.7% hospitalization rate. The highest hospitalization death rate occurred in esomeprazole (91.2%). Conclusion According to our findings, more attention should be paid to SIADH within the first several months after the administration of PPIs. For women older than 65 years, dexlansoprazole may reduce the incidence of PPI-associated SIADH. Nonetheless, larger epidemiological studies are suggested to verify this conclusion. |
| first_indexed | 2024-12-12T13:19:20Z |
| format | Article |
| id | doaj.art-3845e33af275451694fad31a4d1a9b6b |
| institution | Directory Open Access Journal |
| issn | 1471-2369 |
| language | English |
| last_indexed | 2024-12-12T13:19:20Z |
| publishDate | 2022-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Nephrology |
| spelling | doaj.art-3845e33af275451694fad31a4d1a9b6b2022-12-22T00:23:20ZengBMCBMC Nephrology1471-23692022-05-012311810.1186/s12882-022-02818-3Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance studyMengmeng Wang0Lingjian Zhang1Min Jia2Junyan Wang3Zhiwen Shen4Shuyue Wang5Xinghui Zhang6Jing Xu7Zheng Zheng8Xuanrui Lv9Xiaoyu Zong10Hui Li11Jin Zhou12Tong Meng13Mingzhu Chen14Bin Zhao15Jian Gong16Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityDepartment of Pharmacy, Peking Union Medical College HospitalResearch Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical UniversityAbstract Aim The objective of this study was to evaluate the reported associations between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and a variety of proton pump inhibitors (PPI) through analysis of the reports extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods FAERS reports from January 2004 to March 2020 were used to conduct disproportionality and Bayesian analyses. The definition of SIADH relied on the preferred terms provided by the Medical Dictionary for Regulatory Activities. The time to onset, mortality, and hospitalization rates of PPI-related SIADH were also investigated. Results The study identified a total of 273 reports of PPI-associated SIADH, which appeared to influence more elderly than middle-aged patients (71.1% vs. 12.5%). Women were more affected than men (48.7% vs. 41.8%). Rabeprazole had a stronger SIADH association than other PPIs based on the highest reporting odds ratio (reporting odds ratio = 13.3, 95% confidence interval (CI) = 7.2, 24.9), proportional reporting ratio (proportional reporting ratio = 13.3, χ2 = 113.7), and empirical Bayes geometric mean (empirical Bayes geometric mean = 13.3, 95% CI = 7.9). The median time to SIADH onset was 22 (interquartile range 6–692) days after PPI administration. PPI-associated SIADH generally led to a 2.95% fatality rate and a 79.7% hospitalization rate. The highest hospitalization death rate occurred in esomeprazole (91.2%). Conclusion According to our findings, more attention should be paid to SIADH within the first several months after the administration of PPIs. For women older than 65 years, dexlansoprazole may reduce the incidence of PPI-associated SIADH. Nonetheless, larger epidemiological studies are suggested to verify this conclusion.https://doi.org/10.1186/s12882-022-02818-3Syndrome of inappropriate antidiuretic hormone secretionAdverse event reporting systemPharmacoepidemiologyClinical drug evaluationProton pump inhibitors |
| spellingShingle | Mengmeng Wang Lingjian Zhang Min Jia Junyan Wang Zhiwen Shen Shuyue Wang Xinghui Zhang Jing Xu Zheng Zheng Xuanrui Lv Xiaoyu Zong Hui Li Jin Zhou Tong Meng Mingzhu Chen Bin Zhao Jian Gong Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study BMC Nephrology Syndrome of inappropriate antidiuretic hormone secretion Adverse event reporting system Pharmacoepidemiology Clinical drug evaluation Proton pump inhibitors |
| title | Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study |
| title_full | Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study |
| title_fullStr | Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study |
| title_full_unstemmed | Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study |
| title_short | Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study |
| title_sort | syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use a pharmacovigilance study |
| topic | Syndrome of inappropriate antidiuretic hormone secretion Adverse event reporting system Pharmacoepidemiology Clinical drug evaluation Proton pump inhibitors |
| url | https://doi.org/10.1186/s12882-022-02818-3 |
| work_keys_str_mv | AT mengmengwang syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT lingjianzhang syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT minjia syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT junyanwang syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT zhiwenshen syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT shuyuewang syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT xinghuizhang syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT jingxu syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT zhengzheng syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT xuanruilv syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT xiaoyuzong syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT huili syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT jinzhou syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT tongmeng syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT mingzhuchen syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT binzhao syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy AT jiangong syndromeofinappropriateantidiuretichormonesecretionisassociatedwithdifferentprotonpumpinhibitoruseapharmacovigilancestudy |